Skip to content

To check if after using the test products people get pimples.

A Prospective, Randomized, double-blinded, two-cohort, parallel group study to evaluate Comedogenic Potential of Test Products (Cream and Lotion) when Applied Topically Under Occluded Patch to the Skin. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/071597
Enrollment
30
Registered
2024-07-30
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Venusia CeraPlus Cream: Approximately 0.025 g or ml of the test product will be applied on marked zone and occluded by patch for 24 hours on the upper back of each participant by CRA’s

Sponsors

Dr. Reddys Laboratories Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy men and/or women between 18 and 55 years of age 2. Participants displaying prominent follicular orifices on the upper region of the back on visual observation. 3. Having apparently healthy skin on test area. 4. Willing to give written informed consent to participate in the study. 5. Cooperating and ready to comply to protocol procedures. 6. Willingness to avoid intense UV exposure on test area (sun or artificial UV), during the course of the study. 7. Willingness to avoid water contact (i.e.: swimming) or activity which cause sweating (i.e.: exercise, sauna…), during the time when patch is applied on back. 8. Ready to wear loose cotton clothes.

Exclusion criteria

Exclusion criteria: 1. People who have a job involving contact with water or a job which causes perspiration. (Routine work can be done. No carrying out activities like excessive/brisk walking, exercising etc. which will lead to excessive sweating). 2. Pregnant or lactating women confirmed by performing UPT (only for females of child bearing potential). 3. For whom the investigator considers, will be non-compliant. 4. Scars or tattoo on the area to be studied. 5. Dermatological infection/pathology on area to be studied. 6. Hypersensitivity, allergy antecedent (to any cosmetic product, raw material) 7. Any clinically significant systemic or cutaneous disease, which may interfere with study treatments or procedures. 8. Participants on any medical treatment either systemic /hormonal or topical which may interfere with the performance of the study treatment (presently or in the past 3 months). 9. Participant in an exclusion period or participating in any clinical study within 30 days prior to screening.

Design outcomes

Primary

MeasureTime frame
Grading of micro-comedones using light microscopy.Timepoint: Day 1, Day 24

Secondary

MeasureTime frame
NoneTimepoint: Nil

Countries

India

Contacts

Public ContactMs Preetha Paul

Clinical Aesthetics and Investigative Management Service Pvt. Ltd. (C.L.A.I.M.S.PVT.LTD.)

preetha@claimsclinical.com66758851

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026